Use of nomograms as predictive tools in bladder cancer

World Journal of Urology

Volumn 24, Issue 5, 2006, Pages 489-498

  Shabsigh, Ahmad ^a   Bochner, Bernard H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Nomograms; Outcome prediction

Indexed keywords

ALGORITHM; ARTICLE; BLADDER TUMOR; CANCER STAGING; DISEASE COURSE; HUMAN; MORTALITY; NOMOGRAM; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ALGORITHMS; DISEASE PROGRESSION; HUMANS; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33751258291     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-006-0122-y     Document Type: Article

References (62)

1. Jemal A, et al (2006) Cancer statistics. CA Cancer J Clin 56(2):106-130
2. Foresman WH, Messing EM (1997) Bladder cancer: Natural history, tumor markers, and early detection strategies. Semin Surg Oncol 13(5):299-306
3. Pawinski A, et al (1996) A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. Eortc genito-urinary tract cancer cooperative group and the medical research council working party on superficial bladder cancer. Acta Urol Belg 64(2):27
4. Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 171(6 Pt 1):2186-2190
5. Sengupta S, Blute ML (2006) The management of superficial transitional cell carcinoma of the bladder. Urology 67(3 Suppl 1):48-54
6. Miles BJ, Giesler B, Kattan MW (1999) Recall and attitudes in patients with prostate cancer. Urology 53(1):169-174
7. Kattan M (2001) Expert systems in medicine. In: Smelser N, Baltes P (eds) International encyclopedia of the social behavioral sciences. Pergamon, Oxford, pp 5135-5139
8. Kattan MW (2002) Nomograms. Introduction. Semin Urol Oncol 20(2):79-81
9. Kattan MW (2005) When and how to use informatics tools in caring for urologic patients. Nat Clin Pract Urol 2(4):183-190
10. D'Amico AV, et al (2000) Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 55(4):572-577
11. Partin AW, et al (2001) Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58(6):843-848
12. Graefen M, et al (2002) A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 7(4):141-146
13. Kattan MW (2003) Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: Preoperative application in prostate cancer. Curr Opin Urol 13(2):111-116
14. Kattan MW, et al (2003) Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170(5):1792-1797
15. Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17(5):1499-1507
16. Kattan MW, et al (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21(24):4568-4571
17. Smaletz O, et al (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20(19):3972-3982
18. Sargent DJ (2001) Comparison of artificial neural networks with other statistical approaches: Results from medical data sets. Cancer 91(8 Suppl):1636-1642
19. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361-387
20. Jewett H (1946) Infiltrating carcinoma of the bladder: Relation of the depth of penetration of the bladder wall to the incidence of local extension and metastasis. J Urol 55:366
21. Marshall V (1952) The relation of the preoperative estimate to the pathologic demonstration of the extent of vesical neoplasms. J Urol 68:714
22. AJCC (1997) AJCC cancer staging manual, urinary bladder. Fleming ID (ed). Williams & Wilkins, Philadelphia
23. Dohnal V, Kuca K, Jun D (2005) What are artificial neural networks and what they can do? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149(2):221-224
24. Kattan MW (2003) Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 170(6 Pt 2):S6-S9
25. Vogelzang NJ, SP, Shipley WU, Debruyne FMJ, Linehan WM (2005) Comprehensive textbook of genitourinary oncology, 3rd edn. Lippincott & Wilkins, Philadelphia, p 907
26. Sylvester RJ, et al (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66(6 Suppl 1):90-107
27. Kiemeney LA, et al (1993) The clinical epidemiology of superficial bladder cancer. Dutch South-east cooperative urological group. Br J Cancer 67(4):806-812
28. Rubben H, et al (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139(2):283-285
29. Parmar MK, et al (1989) Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: Report from the British medical research council subgroup on superficial bladder cancer (urological cancer working party). J Urol 142(2 Pt 1):284-288
30. Millan-Rodriguez F, et al (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164(3 Pt 1):680-684
31. Millan-Rodriguez F, et al (2000) Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163(1):73-78
32. Oosterlinck W, van der Meijden AP, Sylvester R, Böhle A, Rintala E, Solsona Narvön E, Lobel B (2006) Guidelines on TaT1 (Non-muscle invasive) bladder cancer. Eur Assoc Urol, p. 17
33. Smith JA, LR, Montie JE, Rowland RG, Cockett ATK, Fracchia JA (1999) The management of non-muscle invasive bladder cancer. Am Urol Assoc, p. 68
34. Chatterjee SJ, et al (2004) Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22(6):1007-1013
35. Cordon-Cardo C, et al (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57(7):1217-1221
36. Lacoste-Collin L, et al (2002) Expression of p27(Kip1) in bladder cancers: Immunohistochemical study and prognostic value in a series of 95 cases. Cancer Lett 186(1):115-120
37. Lopez-Beltran A, et al (2004) Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: The role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 122(3):444-452
38. Shariat SF, et al (2005) Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173(5):1518-1525
39. Dutta SC, et al (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166(2):490-493
40. Ficarra V, et al (2005) Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95(6):786-790
41. Dalbagni G, Herr HW, Reuter VE (2002) Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 60(5):822-824
42. Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19(1):89-93
43. Herr HW (2001) Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 174(6):2134-2137
44. Cheng L, et al (2000) Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens. Am J Clin Pathol 113(2):275-279
45. Cummings KB, Barone JG, Ward WS (1992) Diagnosis and staging of bladder cancer. Urol Clin North Am 19(3):455-465
46. Amling CL, et al (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151(1):31-35
47. Skinner DG (1977) Current state of classification and staging of bladder cancer. Cancer Res 37(8 Pt 2):2838-2842
48. Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24(24):3967-3972
49. Mungan NA, et al (2000) Gender differences in stage-adjusted bladder cancer survival. Urology 55(6):876-880
50. Mungan NA, et al (2000) Gender differences in stage distribution of bladder cancer. Urology 55(3):368-371
51. Lee CT, et al (2006) Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 175(4):1262-1267
52. Leibovitch I, et al (1993) The significance of ureteral obstruction in invasive transitional cell carcinoma of the urinary bladder. J Surg Oncol 52(1):31-35
53. Quek ML, et al (2005) Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174(1):103-106
54. Lotan Y, et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23(27):6533-6539
55. Choong NW, Quevedo JF, Kaur JS (2005) Small cell carcinoma of the urinary bladder. The Mayo clinic experience. Cancer 103(6):1172-1178
56. Kamat AM, et al (2006) The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3 Pt 1):881-885
57. Esrig D, et al (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331(19):1259-1264
58. Stein JP, et al (1998) Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90(14):1072-1079
59. Sarkis AS, et al (1995) Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13(6):1384-1390
60. Cote RJ, et al (1997) p53 and treatment of bladder cancer. Nature 385(6612):123-125
61. Karakiewicz PI, et al (2006) Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol (in press)
62. Karakiewicz PI, et al (2006) Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176(4):1354-1352